Lyell Immunopharma (LYEL) said Tuesday its therapy candidate for treating relapsed or refractory large B-cell lymphoma, LYL314, has received the US Food and Drug Administration's Regenerative Medicine Advanced Therapy designation.
The RMAT designation provides all the benefits of Fast Track and Breakthrough Therapy designations, Lyell said. The FDA's designation drew on initial findings from an ongoing phase 1/2 trial, the company said.
Two pivotal trials are expected to start in mid-2025 and early 2026, the company added.
Shares of the company were up 3% in recent Tuesday trading.
Price: 0.46, Change: +0.01, Percent Change: +3.13
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。